• June 3-6, 2024
  • San Diego Convention Center, California



Inimmune Inc.

Tuesday, June 04, 2024
Company Presentation
Company Presentation Theater 1
Inimmune is advancing disruptive disease modifying immunotherapies in the oncology and allergy spaces to improve patient’s lives. We are currently raising a Series B raise to advance our two phase I assets through Phase II. INI-4001, a potent and selective TLR-7/8 agonist, is currently in a phase I trial in cancer patients with solid tumors refractory to check point therapies. INI-4001, in preclinical cancer models, stimulates the innate immune system and synergizes with immune check point therapy to eradicate tumors. This is expected to greatly expand the percentage of patients who will benefit from check point therapy. Our lead allergy therapeutic INI-2004 has completed its multiple ascending dose phase IB trial. Our team is composed of world leaders in innate immune R&D which has resulted in non-dilutive NIH funding (over $140M) over the past 7 years. This NIH funding significantly reduces financial risk and targets investor capital towards advancing our clinical assets.
Inimmune Inc.
Company Website: http://www.Inimmune.com
Lead Product in Development: INI-2004, Immunotherapy to cure allergies
Number Of Unlicensed Products (For Which You Are Seeking Partners): INI-2004 : Allergy Immunotherapeutic INI-4001: Immunotherapeutic for treating cancer Vaccine adjuvants that activate the innate immune system

Company HQ City


Company HQ State


Company HQ Country

United States

CEO/Top Company Official

Alan Joslyn, PhD Chief Executive Officer

Development Phase of Primary Product

Phase I
Primary Speaker
Alan Joslyn, PhD
Chief Executive Officer
Inimmune Inc.
Back to Session List

white squarewhite


Thanks to our sponsors for supporting our mission to drive a revolution to cure patients, protect our climate, and nourish humanity.